Red blood cell transfusion and mortality after transcatheter aortic valve implantation via transapical approach: A propensity-matched comparison from the TRITAVI registry.

Bleeding Mortality RBC transfusion TAVI Transapical

Journal

International journal of cardiology. Heart & vasculature
ISSN: 2352-9067
Titre abrégé: Int J Cardiol Heart Vasc
Pays: Ireland
ID NLM: 101649525

Informations de publication

Date de publication:
Aug 2024
Historique:
received: 26 03 2024
revised: 07 06 2024
accepted: 21 06 2024
medline: 29 7 2024
pubmed: 29 7 2024
entrez: 29 7 2024
Statut: epublish

Résumé

Bleeding is frequent during transcatheter aortic valve implantation (TAVI), especially when performed through a transapical approach (TA), and is associated with a worse prognosis. The present study aims to test the implication of red blood cell (RBC) transfusion and the optimal transfusion strategy in this context. Among 11,265 participants in the multicenter TRITAVI (Transfusion Requirements in Transcatheter Aortic Valve Implantation) registry, 548 patients (4.9%) who received TA-TAVI at 19 European centers were included. One-to-one propensity score matching was performed to reduce treatment selection bias and potential confounding among transfused versus non-transfused patients. The primary endpoint of the study was the 30-day occurrence of all-cause mortality. 209 patients (38 %) received RBC transfusions. The primary endpoint occurred in 47 (8.6 %) patients. Propensity score matching identified 188 pairs of patients with and without RBC transfusion. In the propensity score-matched analysis, RBC transfusion was associated with increased 30-day mortality (HR 3.35, 95 % CI 1.51 - 7.39; p = 0.002). At multivariable cox regression analysis, RBC transfusion was an independent predictor of 30-day mortality (HR 3.07, 95 % CI 1.01-9.41, p = 0.048), as well as baseline ejection fraction (HR 0.96, 95 % CI 0.92-0.99, p = 0.043), and acute kidney injury (HR 3.95, 95 % CI 1.11-14.05, p = 0.034). RBC transfusion is an independent predictor of short-term mortality in patients undergoing TA-TAVI, regardless of major bleeding.Clinical trial registration: https://www.clinicaltrials.gov Unique identifier: NCT03740425.

Identifiants

pubmed: 39070183
doi: 10.1016/j.ijcha.2024.101460
pii: S2352-9067(24)00126-X
pmc: PMC11278079
doi:

Banques de données

ClinicalTrials.gov
['NCT03740425']

Types de publication

Journal Article

Langues

eng

Pagination

101460

Informations de copyright

© 2024 The Author(s).

Déclaration de conflit d'intérêts

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Francesco Radico (F)

Department of Cardiology, ASL2 Abruzzo and Department of Neuroscience, Imaging and Clinical Sciences, 'G. D'Annunzio' University of Chieti-Pescara, Italy.

Fausto Biancari (F)

Department of Medicine, South Karelia Central Hospital, University of Helsinki, Lappeenranta, Finland.

Fabrizio D'Ascenzo (F)

Department of Internal Medicine, Città della Salute e della Scienza, Turin, Italy.

Francesco Saia (F)

Department of Cardiothoracic Vascular, University Hospital, Bologna, Italy.

Giampaolo Luzi (G)

Cardiovascular Department, Azienda Ospedaliera Regionale "San Carlo", Potenza, Italy.

Francesco Bedogni (F)

Department of Cardiology, IRCCS Policlinico San Donato, San Donato Milanese, Milan, Italy.

Ignacio J Amat-Santos (IJ)

CIBERCV, Interventional Cardiology, Hospital Clínico Universitario de Valladolid, Valladolid, Spain.

Vincenzo De Marzo (V)

Department of Cardiology, ASL2 Abruzzo and Department of Neuroscience, Imaging and Clinical Sciences, 'G. D'Annunzio' University of Chieti-Pescara, Italy.
Chair of Cardiovascular Disease, Department of Internal Medicine and Specialties University of Genoa Italy.

Arnaldo Dimagli (A)

Department of Cardiothoracic Surgery, Weill Cornell Medicine, New York, NY, the United States of America.

Timo Mäkikallio (T)

Department of Medicine, South Karelia Central Hospital, University of Helsinki, Lappeenranta, Finland.

Eugenio Stabile (E)

Cardiovascular Department, Azienda Ospedaliera Regionale "San Carlo", Potenza, Italy.

Sara Blasco-Turrión (S)

CIBERCV, Interventional Cardiology, Hospital Clínico Universitario de Valladolid, Valladolid, Spain.

Luca Testa (L)

Department of Cardiology, IRCCS Policlinico San Donato, San Donato Milanese, Milan, Italy.

Marco Barbanti (M)

Division of Cardiology, A.O.U. Policlinico "G. Rodolico - San Marco", Catania, Italy.

Corrado Tamburino (C)

Division of Cardiology, A.O.U. Policlinico "G. Rodolico - San Marco", Catania, Italy.

Italo Porto (I)

Chair of Cardiovascular Disease, Department of Internal Medicine and Specialties University of Genoa Italy.
Cardiology Unit, Cardiothoracic and Vascular Department (DICATOV) IRCCS, Ospedale Policlinico San Martino Genoa Italy.

Franco Fabiocchi (F)

Centro Cardiologico Monzino, IRCCS, Milan, Italy.
Galeazzi-Sant'Ambrogio Hospital, I.R.C.C.S. Milan, Italy.

Federico Conrotto (F)

Department of Internal Medicine, Città della Salute e della Scienza, Turin, Italy.

Francesco Pelliccia (F)

Department of Cardiovascular Sciences, University Sapienza, Rome, Italy.

Giuliano Costa (G)

Division of Cardiology, A.O.U. Policlinico "G. Rodolico - San Marco", Catania, Italy.

Giulio G Stefanini (GG)

IRCCS Humanitas Research Hospital, Rozzano-Milan, Italy.

Andrea Macchione (A)

Cardiology Unit, Cardiothoracic and Vascular Department (DICATOV) IRCCS, Ospedale Policlinico San Martino Genoa Italy.

Michele La Torre (M)

Department of Cardiothoracic Vascular, University Hospital, Bologna, Italy.

Francesco Bendandi (F)

Department of Cardiothoracic Vascular, University Hospital, Bologna, Italy.

Tatu Juvonen (T)

Heart and Lung Center, Helsinki University Central Hospital, University of Helsinki, Helsinki, Finland.

Vincenzo Pasceri (V)

San Filippo Neri Hospital, Rome, Italy.

Wojciech Wańha (W)

Division of Cardiology and Structural Heart Diseases, Medical University of Silesia, Katowice, Poland.

Umberto Benedetto (U)

Department of Cardiac Surgery, University "G. d'Annunzio", Chieti, Italy.

Fabio Miraldi (F)

Department of Cardiovascular Sciences, University Sapienza, Rome, Italy.

Dobromir Dobrev (D)

Institute of Pharmacology, West German Heart and Vascular Center, University Duisburg-Essen, Essen, Germany.
Montréal Heart Institute, Université de Montréal, Montréal, Québec, Canada.
Department of Integrative Physiology, Baylor College of Medicine, Houston, TX, the United States of America.

Marco Zimarino (M)

Department of Cardiology, ASL2 Abruzzo and Department of Neuroscience, Imaging and Clinical Sciences, 'G. D'Annunzio' University of Chieti-Pescara, Italy.

Classifications MeSH